281 related articles for article (PubMed ID: 33184662)
1. Current use and safety of novel oral anticoagulants in adults with congenital heart disease: results of a nationwide analysis including more than 44 000 patients.
Freisinger E; Gerß J; Makowski L; Marschall U; Reinecke H; Baumgartner H; Koeppe J; Diller GP
Eur Heart J; 2020 Nov; 41(43):4168-4177. PubMed ID: 33184662
[TBL] [Abstract][Full Text] [Related]
2. Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study.
Gieling EM; van den Ham HA; van Onzenoort H; Bos J; Kramers C; de Boer A; de Vries F; Burden AM
Br J Clin Pharmacol; 2017 Aug; 83(8):1844-1859. PubMed ID: 28205318
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of nonvitamin K antagonist oral anticoagulants during catheter ablation of atrial fibrillation: A systematic review and meta-analysis.
Ge Z; Faggioni M; Baber U; Sartori S; Sorrentino S; Farhan S; Chandrasekhar J; Vogel B; Qadeer A; Halperin J; Reddy V; Dukkipati S; Dangas G; Mehran R
Cardiovasc Ther; 2018 Oct; 36(5):e12457. PubMed ID: 29971964
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of novel oral anticoagulants in UK patients with non-valvular atrial fibrillation and chronic kidney disease: a matched cohort study.
Loo SY; Coulombe J; Dell'Aniello S; Brophy JM; Suissa S; Renoux C
BMJ Open; 2018 Jan; 8(1):e019638. PubMed ID: 29371284
[TBL] [Abstract][Full Text] [Related]
6. Non-VKA Oral Anticoagulants in Adult Congenital Heart Disease: a Single-Center Study.
Brás PG; Mano TB; Rito T; Castelo A; Ferreira V; Agapito A; Ferreira RC; Pinto F; de Sousa L
Cardiovasc Drugs Ther; 2023 Dec; 37(6):1077-1086. PubMed ID: 35713747
[TBL] [Abstract][Full Text] [Related]
7. Non-vitamin K antagonist oral anticoagulants (NOACs) for thromboembolic prevention, are they safe in congenital heart disease? Results of a worldwide study.
Yang H; Bouma BJ; Dimopoulos K; Khairy P; Ladouceur M; Niwa K; Greutmann M; Schwerzmann M; Egbe A; Scognamiglio G; Budts W; Veldtman G; Opotowsky AR; Broberg CS; Gumbiene L; Meijboom FJ; Rutz T; Post MC; Moe T; Lipczyńska M; Tsai SF; Chakrabarti S; Tobler D; Davidson W; Morissens M; van Dijk A; Buber J; Bouchardy J; Skoglund K; Christersson C; Kronvall T; Konings TC; Alonso-Gonzalez R; Mizuno A; Webb G; Laukyte M; Sieswerda GTJ; Shafer K; Aboulhosn J; Mulder BJM
Int J Cardiol; 2020 Jan; 299():123-130. PubMed ID: 31307847
[TBL] [Abstract][Full Text] [Related]
8. Racial Disparity in the Prescription of Anticoagulants and Risk of Stroke and Bleeding in Atrial Fibrillation Patients.
Tedla YG; Schwartz SM; Silberman P; Greenland P; Passman RS
J Stroke Cerebrovasc Dis; 2020 May; 29(5):104718. PubMed ID: 32122777
[TBL] [Abstract][Full Text] [Related]
9. The Risk of Gastrointestinal Bleeding between Non-Vitamin K Antagonist Oral Anticoagulants and Vitamin K Antagonists in the Asian Atrial Fibrillation Patients: A Meta-Analysis.
Yang KT; Sun WC; Tsai TJ; Tsay FW; Chen WC; Cheng JS
Int J Environ Res Public Health; 2020 Dec; 18(1):. PubMed ID: 33375495
[No Abstract] [Full Text] [Related]
10. Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation.
Briere JB; Bowrin K; Millier A; Toumi M; Wojciechowski P; Taieb V
J Med Econ; 2019 Aug; 22(8):760-765. PubMed ID: 30969801
[No Abstract] [Full Text] [Related]
11. Efficacy and Safety of the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Concomitant Aspirin Therapy: A Meta-Analysis of Randomized Trials.
Bennaghmouch N; de Veer AJWM; Bode K; Mahmoodi BK; Dewilde WJM; Lip GYH; Brueckmann M; Kleine E; Ten Berg JM
Circulation; 2018 Mar; 137(11):1117-1129. PubMed ID: 29101289
[TBL] [Abstract][Full Text] [Related]
12. Trends in the prescription of novel oral anticoagulants in UK primary care.
Loo SY; Dell'Aniello S; Huiart L; Renoux C
Br J Clin Pharmacol; 2017 Sep; 83(9):2096-2106. PubMed ID: 28390065
[TBL] [Abstract][Full Text] [Related]
13. Trends in oral anticoagulant use - A 10-year retrospective analysis from a general medicine department of a tertiary care hospital in south India.
Thomas VV; Lenin A; George TK; Thenmozhi M; Iyadurai R; Sudarsanam TD
J Postgrad Med; 2024 Apr; 70(2):77-83. PubMed ID: 37470633
[TBL] [Abstract][Full Text] [Related]
14. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.
Huisman MV; Ma CS; Diener HC; Dubner SJ; Halperin JL; Rothman KJ; Teutsch C; Schoof N; Kleine E; Bartels DB; Lip GY;
Europace; 2016 Sep; 18(9):1308-18. PubMed ID: 27335063
[TBL] [Abstract][Full Text] [Related]
15. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.
Heidbuchel H; Verhamme P; Alings M; Antz M; Diener HC; Hacke W; Oldgren J; Sinnaeve P; Camm AJ; Kirchhof P
Europace; 2015 Oct; 17(10):1467-507. PubMed ID: 26324838
[TBL] [Abstract][Full Text] [Related]
16. Risk of gastrointestinal bleeding associated with oral anticoagulation and non-steroidal anti-inflammatory drugs in patients with atrial fibrillation: a nationwide study.
Olsen AS; McGettigan P; Gerds TA; Fosbøl EL; Olesen JB; Sindet-Pedersen C; Staerk L; Lock Hansen M; Pallisgaard JL; Køber L; Torp-Pedersen C; Gislason GH; Lamberts M
Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):292-300. PubMed ID: 31742339
[TBL] [Abstract][Full Text] [Related]
17. Comparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran, and rivaroxaban: results from the CRAFT study.
Balsam P; Ozierański K; Tymińska A; Żukowska K; Zaleska M; Szepietowska K; Maciejewski K; Peller M; Grabowski M; Lodziński P; Praska-Ogińska A; Zaboyska I; Kołtowski Ł; Kowalczuk A; Bednarski J; Filipiak KJ; Opolski G
Kardiol Pol; 2018; 76(5):889-898. PubMed ID: 29350386
[TBL] [Abstract][Full Text] [Related]
18. Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life.
Giustozzi M; Vedovati MC; Verdecchia P; Pierpaoli L; Verso M; Conti S; Cianella F; Marchesini E; Filippucci E; Agnelli G; Becattini C
Eur J Intern Med; 2016 Sep; 33():42-6. PubMed ID: 27394924
[TBL] [Abstract][Full Text] [Related]
19. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
Steffel J; Verhamme P; Potpara TS; Albaladejo P; Antz M; Desteghe L; Haeusler KG; Oldgren J; Reinecke H; Roldan-Schilling V; Rowell N; Sinnaeve P; Collins R; Camm AJ; Heidbüchel H;
Eur Heart J; 2018 Apr; 39(16):1330-1393. PubMed ID: 29562325
[TBL] [Abstract][Full Text] [Related]
20. Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.
Falissard B; Picard F; Mahe I; Hanon O; Touzé E; Danchin N; Lamy FX; Ricci L; Steg PG
Arch Cardiovasc Dis; 2019; 112(6-7):400-409. PubMed ID: 31014991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
